Stada Pharmaceutical has a total of 450 patents globally, out of which 199 are granted. Out of these 450 patents, 44.22% are currently active. Stada has filed the maximum number of patents in Europe (EPO), followed by Germany, the United States of America, and Canada, making these regions its major innovation hubs. In line with this, Europe (EPO) also serves as Stada’s primary R&D focus area. The company is headquartered in Bad Vilbel, Germany.
Stada Pharmaceutical, founded in 1895, is one of the world’s leading pharmaceutical companies. Stada specializes in the development, manufacturing, and marketing of generic medicines, OTC products, biosimilars, and specialty pharmaceuticals. The company’s portfolio spans multiple therapeutic areas, including central nervous system disorders, cardiovascular diseases, oncology, and respiratory conditions. With a strong global footprint and over a century of expertise, Stada plays a key role in enhancing patient access to high-quality, affordable healthcare worldwide.
Do read about some of the most popular patents of Stada Pharmaceutical which have been covered by us in this article and also you can find Stada Pharmaceutical patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Stada Pharmaceutical patent portfolio.
How many patents does Stada Pharmaceutical have?
Stada Pharmaceutical has a total of 450 patents globally. These patents belong to 162 unique patent families. Out of 450 patents, 198 patents are active.
How Many Patents did Stada Pharmaceutical File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Stada Pharmaceutical Applications Filed | Stada Pharmaceutical Patents Granted |
| 2025 | 2 | 9 |
| 2024 | 8 | 18 |
| 2023 | 14 | 10 |
| 2022 | 5 | 10 |
| 2021 | 23 | 14 |
| 2020 | 6 | 15 |
| 2019 | 14 | 12 |
| 2018 | 3 | 8 |
| 2017 | 15 | 9 |
| 2016 | 31 | 12 |
How many Stada Pharmaceutical patents are Alive/Dead?
Worldwide Patents
How Many Patents did Stada Pharmaceutical File in Different Countries?
Top Countries in which Stada Pharmaceutical Filed Patents
| Country | Patent |
| Europe (EPO) | 79 |
| Germany | 28 |
| United States Of America | 26 |
| Canada | 19 |
| Australia | 16 |
| Spain | 16 |
| Japan | 15 |
| South Korea | 14 |
| Portugal | 12 |
| China | 12 |
| Poland | 10 |
| Singapore | 10 |
| Denmark | 9 |
| Austria | 9 |
| Serbia | 7 |
| Czech Republic | 7 |
| Hong Kong | 7 |
| Malaysia | 6 |
| India | 6 |
| Brazil | 5 |
| Mexico | 5 |
| South Africa | 4 |
| Croatia | 4 |
| Russia | 4 |
| Taiwan | 4 |
| Viet Nam | 4 |
| Ireland | 3 |
| Israel | 3 |
| Thailand | 3 |
| New Zealand | 3 |
| Indonesia | 3 |
| Philippines | 3 |
| Slovenia | 3 |
| United Kingdom | 3 |
| Turkey | 3 |
| Latvia | 3 |
| Bulgaria | 3 |
| Hungary | 2 |
| Argentina | 2 |
| Ukraine | 2 |
| Colombia | 2 |
| Romania | 2 |
| Georgia | 2 |
| Eurasia | 2 |
| Cuba | 2 |
| Sweden | 1 |
| Lithuania | 1 |
| Tunisia | 1 |
| Slovakia | 1 |
| Saudi Arabia | 1 |
| France | 1 |
| Gulf Cooperation Council | 1 |
| Costa Rica | 1 |
| Morocco | 1 |
| Mongolia | 1 |
| Macao | 1 |
Where are Research Centres of Stada Pharmaceutical Patents Located?
10 Best Stada Pharmaceutical Patents
US20090247450A1 is the most popular patent in the Stada Pharmaceutical portfolio. It has received 34 citations so far from companies like Companies, Novo Nordisk A/S, Ratiopharm Gmbh and Pfizer Products Inc.
Below is the list of 10 most cited patents of Stada Pharmaceutical:
| Publication Number | Citation Count |
| US20090247450A1 | 34 |
| US20110038516A1 | 25 |
| US20080193491A1 | 24 |
| US20130110046A1 | 21 |
| US20100006095A1 | 20 |
| US20070036860A1 | 18 |
| US20070243597A1 | 15 |
| WO2007009950A1 | 16 |
| WO2017039525A1 | 13 |
| WO2008041031A1 | 11 |
Stada Patent Expiry:
A number of STADA patents have expired due to different administrative and legal reasons. The main causes are listed below:
| Reason for Expiry | Number of Patents |
| Non-payment | 36 |
| Rejected | 32 |
| Discontinuation | 18 |
| Ceased | 12 |
| Abandoned | 10 |
| Revoked | 6 |
Most expiries happened because of non-payment of maintenance fees, followed by rejections during prosecution. Others were discontinued, ceased, abandoned, or revoked based on compliance and legal outcomes.
Top 10 Companies Challenging STADA’s Patents
Analysis of STADA’s European (EP) patent shows active opposition from multiple players, with the number of oppositions per company ranging from 4 to 7. This indicates a competitive landscape where certain patents are highly targeted, reflecting strong interest in challenging STADA’s intellectual property.
What are Stada Pharmaceutical key innovation segments?
What Technologies are Covered by Stada Pharmaceutical?
The chart below distributes patents filed by Stada Pharmaceutical in different countries on the basis of the technology protected in patents. It also represents the markets where Stada Pharmaceutical thinks it’s important to protect particular technological inventions.
R&D Focus: How has Stada Pharmaceutical search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Stada Pharmaceutical?
